BRIEF-Vimy Pharma Files Health Canada Submission For Generic Ozempic® (Semaglutide)

May 28 (Reuters) -

  • VIMY PHARMA FILES HEALTH CANADA SUBMISSION FOR GENERIC OZEMPIC® (SEMAGLUTIDE)

  • VIMY PHARMA: CO'S GENERIC SEMAGLUTIDE PRODUCT IS EXPECTED TO PROVIDE CANADIANS WITH LOWER-COST ALTERNATIVE TO BRANDED GLP-1 THERAPIES

Source text: ID:nCNWNZ4Dja


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.